Elizabeth Anderson
Stock Analyst at Evercore ISI Group
(2.57)
# 2,188
Out of 5,152 analysts
144
Total ratings
55.56%
Success rate
-0.99%
Average return
Main Sectors:
Stocks Rated by Elizabeth Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XRAY DENTSPLY SIRONA | Maintains: In-Line | $12 → $15 | $13.33 | +12.53% | 9 | Feb 27, 2026 | |
| TDOC Teladoc Health | Maintains: In-Line | $8 → $5 | $5.12 | -2.34% | 7 | Feb 26, 2026 | |
| MDLN Medline | Maintains: Outperform | $50 → $55 | $44.05 | +24.86% | 2 | Feb 26, 2026 | |
| HSIC Henry Schein | Maintains: Outperform | $90 → $100 | $80.17 | +24.73% | 3 | Feb 25, 2026 | |
| WAY Waystar Holding | Maintains: Outperform | $40 → $27 | $26.58 | +1.58% | 5 | Feb 18, 2026 | |
| HNGE Hinge Health | Maintains: Outperform | $65 → $50 | $45.84 | +9.08% | 3 | Feb 11, 2026 | |
| DGX Quest Diagnostics | Maintains: In-Line | $190 → $220 | $203.98 | +7.85% | 5 | Feb 11, 2026 | |
| ALGN Align Technology | Maintains: Outperform | $180 → $200 | $175.60 | +13.90% | 16 | Feb 5, 2026 | |
| FTRE Fortrea Holdings | Upgrades: Outperform | $14 → $25 | $9.92 | +152.02% | 11 | Jan 6, 2026 | |
| PRVA Privia Health Group | Maintains: Outperform | $28 → $30 | $23.84 | +25.84% | 5 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $28 | $13.60 | +105.88% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $70 | $26.07 | +168.51% | 10 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $190 → $220 | $216.02 | +1.84% | 10 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $95 | $78.69 | +20.73% | 10 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $220 → $240 | $178.50 | +34.45% | 7 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $4 → $3 | $1.93 | +55.44% | 9 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $305 | $275.92 | +10.54% | 7 | Oct 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $800 → $825 | $931.35 | -11.42% | 7 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $23 | $27.93 | -17.65% | 4 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $5 → $3 | $0.66 | +351.47% | 5 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $68 → $26 | $1.73 | +1,417.34% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $35 → $15 | $1.69 | +787.57% | 3 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 | $0.80 | +1,278.62% | 2 | Jan 4, 2022 |
DENTSPLY SIRONA
Feb 27, 2026
Maintains: In-Line
Price Target: $12 → $15
Current: $13.33
Upside: +12.53%
Teladoc Health
Feb 26, 2026
Maintains: In-Line
Price Target: $8 → $5
Current: $5.12
Upside: -2.34%
Medline
Feb 26, 2026
Maintains: Outperform
Price Target: $50 → $55
Current: $44.05
Upside: +24.86%
Henry Schein
Feb 25, 2026
Maintains: Outperform
Price Target: $90 → $100
Current: $80.17
Upside: +24.73%
Waystar Holding
Feb 18, 2026
Maintains: Outperform
Price Target: $40 → $27
Current: $26.58
Upside: +1.58%
Hinge Health
Feb 11, 2026
Maintains: Outperform
Price Target: $65 → $50
Current: $45.84
Upside: +9.08%
Quest Diagnostics
Feb 11, 2026
Maintains: In-Line
Price Target: $190 → $220
Current: $203.98
Upside: +7.85%
Align Technology
Feb 5, 2026
Maintains: Outperform
Price Target: $180 → $200
Current: $175.60
Upside: +13.90%
Fortrea Holdings
Jan 6, 2026
Upgrades: Outperform
Price Target: $14 → $25
Current: $9.92
Upside: +152.02%
Privia Health Group
Nov 7, 2025
Maintains: Outperform
Price Target: $28 → $30
Current: $23.84
Upside: +25.84%
Nov 7, 2025
Maintains: Outperform
Price Target: $27 → $28
Current: $13.60
Upside: +105.88%
Nov 7, 2025
Maintains: Outperform
Price Target: $81 → $70
Current: $26.07
Upside: +168.51%
Oct 31, 2025
Maintains: Outperform
Price Target: $190 → $220
Current: $216.02
Upside: +1.84%
Oct 30, 2025
Maintains: Outperform
Price Target: $85 → $95
Current: $78.69
Upside: +20.73%
Oct 8, 2025
Maintains: Outperform
Price Target: $220 → $240
Current: $178.50
Upside: +34.45%
Oct 8, 2025
Maintains: In-Line
Price Target: $4 → $3
Current: $1.93
Upside: +55.44%
Oct 3, 2025
Maintains: Outperform
Price Target: $300 → $305
Current: $275.92
Upside: +10.54%
Sep 24, 2025
Maintains: Outperform
Price Target: $800 → $825
Current: $931.35
Upside: -11.42%
Jul 9, 2025
Maintains: Outperform
Price Target: $19 → $23
Current: $27.93
Upside: -17.65%
Jul 9, 2025
Maintains: In-Line
Price Target: $5 → $3
Current: $0.66
Upside: +351.47%
Mar 16, 2022
Maintains: In-Line
Price Target: $68 → $26
Current: $1.73
Upside: +1,417.34%
Mar 2, 2022
Downgrades: In-Line
Price Target: $35 → $15
Current: $1.69
Upside: +787.57%
Jan 4, 2022
Downgrades: In-Line
Price Target: $11
Current: $0.80
Upside: +1,278.62%